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Abstract
ORIG INAL ART ICLE
Background Sepsis and inflammation can cause intensive care unit-acquired weakness (ICUAW). Increased
interleukin-6 (IL-6) plasma levels are a risk factor for ICUAW. IL-6 signalling involves the glycoprotein 130 (gp130) re-
ceptor and the JAK/STAT-pathway, but its role in sepsis-induced muscle wasting is uncertain. In a clinical observational
study, we found that the IL-6 target gene, SOCS3, was increased in skeletal muscle of ICUAW patients indicative for
JAK/STAT-pathway activation. We tested the hypothesis that the IL-6/gp130-pathway mediates ICUAW muscle
atrophy.
Methods We sequenced RNA (RNAseq) from tibialis anterior (TA) muscle of cecal ligation and puncture-operated
(CLP) and sham-operated wildtype (WT) mice. The effects of the IL-6/gp130/JAK2/STAT3-pathway were investigated
by analysing the atrophy phenotype, gene expression, and protein contents of C2C12 myotubes. Mice lacking Il6st,
encoding gp130, in myocytes (cKO) and WT controls, as well as mice treated with the JAK2 inhibitor AG490 or vehicle
were exposed to CLP or sham surgery for 24 or 96 h.
Results Analyses of differentially expressed genes in RNAseq (≥2-log2-fold change, P< 0.01) revealed an activation of
IL-6-signalling and JAK/STAT-signalling pathways in muscle of septic mice, which occurred after 24 h and lasted at
least for 96 h during sepsis. IL-6 treatment of C2C12 myotubes induced STAT3 phosphorylation (three-fold,
P < 0.01) and Socs3 mRNA expression (3.1-fold, P < 0.01) and caused myotube atrophy. Knockdown of Il6st dimin-
ished IL-6-induced STAT3 phosphorylation (30.0%; P < 0.01), Socs3 mRNA expression, and myotube atrophy.
JAK2 ( 29.0%; P < 0.01) or STAT3 inhibition (38.7%; P < 0.05) decreased IL-6-induced Socs3 mRNA expression.
Treatment with either inhibitor attenuated myotube atrophy in response to IL-6. CLP-operated septic mice showed
an increased STAT3 phosphorylation and Socs3 mRNA expression in TA muscle, which was reduced in septic Il6st-
cKO mice by 67.8% (P < 0.05) and 85.6% (P < 0.001), respectively. CLP caused a loss of TA muscle weight, which
was attenuated in Il6st-cKO mice (WT: 22.3%, P < 0.001, cKO: 13.5%, P < 0.001; WT vs. cKO P < 0.001). While
loss of Il6st resulted in a reduction of MuRF1 protein contents, Atrogin-1 remained unchanged between septic WT
and cKO mice. mRNA expression of Trim63/MuRF1 and Fbxo32/Atrogin-1 were unaltered between CLP-treated WT
and cKO mice. AG490 treatment reduced STAT3 phosphorylation (22.2%, P < 0.05) and attenuated TA muscle atro-
phy in septic mice (29.6% relative reduction of muscle weight loss, P < 0.05). The reduction in muscle atrophy was
accompanied by a reduction in Fbxo32/Atrogin-1-mRNA (81.3%, P < 0.05) and Trim63/MuRF1-mRNA expression
(77.6%, P < 0.05) and protein content.
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Introduction
Intensive care unit-acquired weakness (ICUAW) affects up to
90% of patients with severe sepsis increasing their morbidity
and mortality.1,2 ICUAW is characterized by a loss of muscle
mass, a reduction in myofibre size, and a decreased muscle
strength leading to persisting physical impairment.3 This phe-
notype results from a dysregulated protein homeostasis with
increased protein degradation and decreased protein synthe-
sis, eventually causing a decrease of muscle structural
proteins.4,5 In ICUAW, atrophy predominantly occurs in fast
twitch/type II myofibres6 and is mainly mediated by the
ubiquitin-proteasome system. The E3 ligase muscle RING-fin-
ger protein-1 (MuRF1), encoded by Trim63, and the F-Box
protein Atrogin-1, encoded by Fbxo32, are key factors for
ubiquitin-proteasome system-mediated protein degradation
in muscle atrophy.7 Both MuRF1 and Atrogin-1 are increased
early and persistently during critical illness and possibly medi-
ate muscle atrophy in ICUAW patients.4,6 Inflammation and
sepsis are major risk factors for ICUAW.8,9 Previously, we re-
ported that interleukin 1β (IL-1β)10 and the acute-phase pro-
tein serum amyloid A1 (SAA1)11,12 promote muscle atrophy in
sepsis, and that their inhibition attenuated sepsis-induced
muscle atrophy in mice. Both IL-1β and SAA1 signalling con-
verge on the transcription factor NF-ĸB (nuclear factor
‘kappa-light-chain-enhancer’ of activated B-cells) and in-
crease the expression of interleukin 6 (IL-6).10–12 IL-6 regu-
lates protein homeostasis in the skeletal muscle.13,14 While
an acute increase in systemic IL-6 promotes muscle growth
and hypertrophy, its sustained elevation, as occurring in can-
cer or diabetes, causes muscle atrophy.15,16 However, the role
of IL-6 signalling in sepsis-induced muscle atrophy is not well
understood.
IL-6 can signal through the canonical pathway, where IL-6
binds to its α-receptor (IL-6R) on the cell surface, and induces
homodimerization and association with the signal transduc-
ing β-receptor glycoprotein 130 (gp130, encoded by Il6st). Al-
ternatively, IL-6 can use the trans-signalling pathway, where it
binds to a soluble IL-6R, which associates with gp130. In both
pathways, the activated IL-6R-gp130 complex binds and acti-
vates the Janus kinase (JAK) family of tyrosine kinases, pri-
marily JAK1, JAK2, and TYK2, which phosphorylate the
cytoplasmatic tail of gp130, enabling the association of the
Signal Transducer and Activator of Transcription (STAT),
mainly STAT1 and STAT3. Phosphorylated STAT (i.e. STAT3
Y705) proteins dimerize and translocate to the nucleus where
they control the expression of their target genes, such as Sup-
pressor of Cytokine Signalling 3 (SOCS3).17,18 SOCS3 acts as a
negative feedback inhibitor of cytokine signalling by inhibi-
tion of JAK1, JAK2, and Tyk2.19 In vitro, SOCS3 also inhibits
the Insulin/PI3K/Akt pathway as a substrate recognition com-
ponent of an E3 ubiquitin ligase complex, degrading Insulin
Receptor Substrate 1 (IRS-1) that is essential for insulin
signalling.20 Insulin increases protein synthesis21 and de-
creases atrogene expression and protein degradation22 via
the PI3K/Akt pathway in mice. This promotes muscle growth
and inversely perturbations can aggravate muscle atrophy
that is frequently seen in critically ill patients.23 Based on
these data and together with our observation that increased
IL-6 plasma level is a risk factor for Critical Illness Myopathy
(CIM) in patients,8 we hypothesized that the IL-6/gp130/




The institutional review board of the Charité
Universitätsmedizin Berlin, Germany, approved the study,
and written informed consent was obtained from legal proxy
[intensive care unit (ICU) patients], or the patients them-
selves before inclusion in the study (Charité EA2/061/06;
http://www.controlled-trials.com, ISRCTN77569430). Clinical
data were reported previously.11 We analysed mRNA expres-
sion in biopsy specimens obtained from the vastus lateralis
muscle of patients at high risk to develop ICUAW. Accord-
ingly, these patients (n = 5) were critically ill, mechanically
ventilated with a SOFA score ≥8 on three consecutive days
within the first 5 days after ICU admission. Biopsy specimens
were taken at Day 5 and Day 15 after ICU admission. Five
age-matched and gender-matched patients undergoing elec-
tive orthopaedic surgery permitted muscle biopsies and were
used as controls. For more details on the clinical data, please
refer to Wollersheim et al. and Langhans et al.4,11
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Animal model of polymicrobial sepsis
All animal procedures were performed in accordance with
the guidelines of the Max-Delbrück Center for Molecular
Medicine and the Charité-Universitätsmedizin Berlin, and
were approved by the Landesamt für Gesundheit und Soziales
(LAGeSo, Berlin, Germany; permit number G 207/13). The
investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1985), as well
as the current version of German Law on the Protection of
Animals.
Klaus Rajewsky kindly provided conditional Il6st knockout
(KO) mice.24 Il6stloxP/loxP mice were crossed with Cre carrying
mice controlled by myoblast-specific Pax7-promotor (Pax7-
Cre) (cKO, Il6stloxP/loxP; Pax7-Cre). Pax7-Cre-negative littermates
were used as controls (WT, Il6stloxP/loxP). Genotyping was per-
formed as recently described10 using primer pairs shown in
Supporting information Table S1.
Cecal ligation and puncture (CLP) surgery was performed
in 12- to 16-week-old male Il6st cKO mice and WT littermate
controls, as recently described.10,25 Sham mice were treated
identically except for the ligation and puncture of the cecum.
The effects of AG490 treatment on sepsis-induced muscle at-
rophy were investigated in 20-week-old male C57BL/6J mice.
Animals received vehicle (10 μL DMSO in 240 μL normal sa-
line) or AG490 (16 mg/kg in 250 μL vehicle) 60 min prior to,
and every 24 h after surgery for 96 h.
Mice were sacrificed 24 or 96 h after surgery, as indicated,
and tibialis anterior (TA) and gastrocnemius/plantaris (GP)
muscles were harvested for analysis. Body, muscle, and organ
weight was measured and normalized to tibia length. Mea-
surements of plasma IL-6 were performed using the Mouse
ELISA Quantikine Kit for IL-6 (R&D Systems, MN, USA) accord-
ing to the manufacturers’ protocol.
RNA sequencing and statistical analyses
Three biological replicates of WT sham and WT CLP 24 and
96 h after surgery were sequenced. Total RNA analyses were
evaluated by an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Inc., CA, USA). Library preparation of 500 ng RNA was
performed using the Illumina TruSeq Stranded mRNA Kit.
cDNA was evaluated and sequencing was performed using
an Illumina HiSeq 4000 sequencer. The transcriptome data
can be found under EBI Annotare v.2.0 (E-MTAB-10960).
Pathway enrichment analysis was performed using DAVID
(Database for Annotation, Visualization and Integrated Dis-
covery) Bioinformatics Resources 6.8 (https://david.ncifcrf.
gov) using the outputs BP_ALL (all biological process terms).
For further information, please refer to the supporting
information.
Histological analyses
Tibialis anterior and gastrocnemius/plantaris muscles were
flash frozen in liquid nitrogen with gum tragacanth (Merck
KGaA, Germany), cut with a thickness of 5 μm and stained
with metachromatic ATPase. One hundred myocyte
cross-sectional areas (MCSAs) were measured per mouse,
muscle and condition in a blinded fashion.
Myoblast culture, differentiation, and atrophy
assay
Cell culture experiments were performed in 5 days differenti-
ated C2C12 cells (American Type Culture Collection,Manassas,
VA, USA). Myocytes were treated with 10 ng/mL of recombi-
nant IL-6 (R&D Systems, MN, USA) or solvent (0.1% bovine se-
rum albumin in phosphate-buffered saline) for the indicated
times. The JAK2 inhibitor AG490 (10 μM, Sigma-Aldrich, MO,
USA), and two STAT3 inhibitors (C188-9; 10 μM, Merck-
Millipore, Germany; S3i-201, 10 μM, Selleckchem) were added
60 min prior to IL-6 treatment. For siRNA transfection we used
the Dharmacon SmartPool siRNA targeting Il6st (J-040007-09-
0005, Dharmacon/Fisher Scientific; control siRNA D-001810-
10-05). Transfection was performed as per the manufacturer’s
protocol. Light microscopy pictures were analysed using the
Leica CTR 6500 microscope and the Leica DFC 360 FX digital
camera. Out of 100 myotubes per condition, three diameters
per myotube were measured and averaged using the ImageJ
software in a blinded fashion.
RNA isolation, cDNA synthesis, and quantitative
real-time-polymerase chain reaction
RNA isolation was performed using TRIzol® Reagent
(Invitrogen™, Life Technologies Corporation, CA, USA) and
the FastPrep-24™ instrument (MP Biomedicals GmbH). Super-
Script® First-Strand Synthesis System (Invitrogen™, Life Tech-
nologies Corporation, CA, USA) was used for cDNA
synthesis. Quantitative real-time polymerase chain reaction
(qRT-PCR) was performed using Power SYBR® Green PCR
Master Mix (Thermo Fischer Scientific Inc., MA, USA) and
self-designed primers (for primer sequences, refer to Table
S2). PCR reactions were performed in a StepOnePlus™
thermocycler (Applied Biosystems). Gene expression was nor-
malized to glyceraldehyde-3-phosphate dehydrogenase
(Gapdh).
Protein extraction and Western blot assay
Muscle tissue was homogenized in lysis buffer using the
FastPrep-24™ instrument. Lysates were separated by
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SDS-PAGE and transferred to PVDF or nitrocellulose mem-
branes (GE Healthcare, Germany). Membranes were incu-
bated with the indicated primary and secondary antibodies.
The antibodies used are indicated in the supporting informa-
tion. GAPDH was used as loading control. We used the
SuperSignal® West Pico Chemiluminescent substrate (Thermo
Fischer Scientific Inc., MA, USA) and Chemiluminescence de-
tection films (GE Amersham, UK) for protein visualization.
Statistics
All experiments were performed independently and at least
three times using biological triplicates each. For mRNA ex-
pression, myotube diameter and MCSA data from cell culture
experiments, a paired t test was used. Data on muscle weight
and mRNA expression were analysed using the Mann–Whit-
ney U test. In vitro data are shown as mean ± SD and
in vivo data are mean ± SEM. Frequency-distribution histo-
grams plotting myotube width or MCSA against its frequency.
Differences were considered statistically significant at
P ≤ 0.05. The GraphPad Prism® 8 program (GraphPad Soft-
ware, La Jolla, CA, USA), Adobe Illustrator CS6, version
16.0.0, and Photoshop CS6, version 13.0 were used to per-
form statistics and draw graphics, respectively.
Results
Interleukin 6 signalling is activated in skeletal
muscle during sepsis
We analysed SOCS3 mRNA expression in muscle biopsy spec-
imens of ICUAW patients and control subjects. qRT-PCR anal-
ysis showed an increased SOCS3 mRNA expression in the
vastus lateralis of critically ill patients at day five and day 15
after ICU-admission compared to controls (Figure 1A) indica-
tive for an activation of the IL-6/JAK/STAT pathway.
To confirm that the IL-6/JAK/STAT pathway is activated in
muscle during sepsis, we performed next generation se-
quencing of RNAs (RNAseq) isolated from TA muscles of CLP
and sham operated WT mice and analysed these data for
changes in the expression of the IL-6 cytokine family and its
receptors. Il6, Il6st, and Il6ra expression was significantly in-
creased in muscle after 24 and 96 h of sepsis, whereas the
other IL-6 family members showed only minor changes (i.e.
Ctf1 and Cntf) or a reduction of gene expression (i.e. Lif and
Lifr) (Figure 1B). Analyses of all differentially expressed genes
(DEG; ≥2-log2-fold change, adjusted P value <0.01) by
Voronoi plots showed an enrichment of IL-6 and IL-6 related
genes after 24 h, which was even more pronounced after
96 h of sepsis (Figure 1C, Figure S1). These data show that
IL-6 signalling is activated in the TA muscle of septic mice.
Further, gene ontology (GO) term analysis (biological pro-
cess) revealed a significant enrichment of genes belonging
to transcription, translation, autophagy, and proteasomal
protein degradation and a decrease in genes involved in
TGFβ-signalling and skeletal system development after 24
but not 96 h (Figure S2). Kyoto Encyclopedia of Genes and
Genomes (KEGG)-pathway analysis showed that insulin resis-
tance and tumour necrosis factor-signalling were increased
and TGFβ and insulin signalling were decreased after 24 h
but not 96 h (Figure S2). Next, we defined a subgroup
encompassing 1036 genes that were up-regulated (Figure
1D) and 1621 genes that were down-regulated at both time
points in sepsis (Figure S3). GO term analysis of
up-regulated DEG showed an enrichment of
ubiquitin-dependent protein degradation. In accordance with
our previous data,10,11 we found an increase in cellular re-
sponse to IL-1 and acute-phase response, as well as IL-6 sig-
nalling and positive regulation of JAK/STAT signalling. KEGG
pathway analysis revealed an increase in DEG involved in pro-
teasomal protein degradation, TNF-signalling and JAK/STAT-
signalling, and insulin resistance (Figure 1D). A strong dereg-
ulation of DEG contained in ‘cellular response to IL6’
(GO:0071354) (Figure 1E), ‘IL-6 production’ (GO:0032635)
(Figure S4), and ‘receptor signalling pathway via JAK-STAT’
(GO:0007259) (Figure S5) indicated an activation of IL-6 sig-
nalling in muscle of septic mice after 24 and 96 h. Collectively,
our data indicate that the IL-6 and JAK/STAT pathways are ac-
tivated in muscle of septic mice after 24 and 96 h.
Interleukin 6 induces atrophy via the gp130/JAK/
STAT pathway in C2C12 myotubes
To analyse IL-6 signalling in myocytes, we treated differenti-
ated murine C2C12 myotubes with recombinant IL-6 or sol-
vent. Western blot analysis showed an increased STAT3
Y705 phosphorylation after 5 to 60 min of IL-6 treatment
(Figure 2A). qRT-PCR revealed that IL-6 increased Socs3
mRNA expression after 24 to 72 h (Figure 2B). IL-6 induced
a reduction in myotube diameter by 11.1%, 9.7%, and 7.1%
at 24, 48, and 72 h, respectively (Figure 2C and 2D). These
data indicate that IL-6 activates the JAK/STAT3 pathway and
causes atrophy of myocytes in vitro.
We next reduced gp130, encoded by Il6st, by siRNA prior
to IL-6 treatment in C2C12 myotubes. Knockdown was con-
firmed by qRT-PCR (relative reduction 69%, P < 0.005; Figure
3A) and immunoblotting (Figure 3B). Knockdown of Il6st at-
tenuated IL-6-induced STAT3 Y705 phosphorylation (Figure
3B), Socs3 expression (Figure 3C) and IL-6-mediated reduc-
tion of myotube diameters compared to siRNA controls
(8.3% vs. 28.3%, P < 0.01; Figure 3D). C2C12 myotubes were
treated with the JAK2 inhibitor AG490 or the STAT3 inhibitor
C188-9 prior to IL-6 treatment. Both inhibitors attenuated IL-
6-induced STAT3 Y705 phosphorylation (Figure 3E) and Socs3
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Figure 1 The IL-6 pathway is activated in skeletal muscle during sepsis. (A) SOCS3 mRNA expression in muscle of critically ill patients. Muscle biopsy
specimens from critically ill patients were obtained from the vastus lateralis muscle on Day 5 (n = 25) and Day 15 (n = 19) in intensive care unit
(ICU). Healthy individuals (n = 5) served as controls. Data are presented as fold change (mean ± SEM). *P< 0.05. (B–E) WT mice were subjected to cecal
ligation and puncture (CLP) or sham surgery. RNA sequencing analyses were performed 24 and 96 h after surgery (WT sham, n = 3; WT CLP, n = 3, for both
time points). (B) Gene expression of known IL6-family members and their receptors in TA muscle of sham- and CLP-operated mice after 24 and 96 h. (C)
Voronoi plot of differentially expressed genes (log2 fold change≥2, adjusted P value<0.05) from RNA sequencing analysis is shown. Voronoi-plots show
the respective GO terms (left panels) and the enriched genes (right panel) per time point (top panels 24 h, bottom panels 96 h) as indicated. Insets lo-
calize IL-6- and JAK/STAT pathway. (D) Venn diagram showing the number of genes that were increased (log2 fold change≥2, adjusted P value<0.01) in
the tibialis anterior muscle compared with sham treated mice after 24 h, 96 h or at both time points. The DAVID functional annotation tool was used for
gene ontology (GO) term-pathway and Kyoto Encyclopedia of Genes and Genomes (KEGG)-pathway analyses of each individual time point, and 10 of the
most enriched biological processes and pathways are shown. (E) Heat map of genes contained in GO-term 0071354 cellular response to IL-6 that were
significantly regulated (P value <0.05) in TA muscle of septic mice 24 and 96 h after surgery when compared to TA of sham operated mice.
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expression (Figure 3F). IL-6-induced atrophy was attenuated
by AG490, C188-9, and S3i-201 (Figures 3G, 3H and S6). These
findings reveal that the gp130/JAK2/STAT3 pathway mediates
IL-6-induced myotube atrophy.
Skeletal muscle specific deletion of Il6st attenuates
sepsis-induced muscle atrophy in mice
To verify our data in vivo, we generated mice deficient
in Il6st in the myocyte lineage. Mice bearing a conditional
Il6stloxP/loxP allele were bred with mice expressing the
Cre-recombinase under the control of the Pax7 promoter
(Il6stloxP/loxP//Pax7Cre, cKO). Il6stloxP/loxP littermates not ex-
pressing Pax7-Cre served as controls (WT). We performed
CLP surgery to induce polymicrobial sepsis for 24 h (to ana-
lyse gp130 signalling; WT: n = 6; cKO: n = 4) and 96 h (to an-
alyse muscle atrophy; WT: n = 15; cKO: n = 10). Sham
operated littermates (24 h: WT: n = 4; cKO: n = 4; 96 h: WT:
n = 6; cKO: n = 6) served as controls. qRT-PCR analysis con-
firmed Il6st deletion in TA of cKO mice (Figure S7A). At base-
line, cKO mice showed no differences in survival, body
Figure 2 Interleukin 6 activates the JAK/STAT signalling pathway and induces atrophy in myocytes. Five days differentiated C2C12 myotubes were
treated with interleukin 6 (IL-6, 10 ng/mL, n = 3) or solvent control (0.1% bovine serum albumin in phosphate-buffered saline, n = 3) for the indicated
time points. (A) Western blot analysis with anti-phospho-STAT3-Tyr705 (pSTAT3 Y705), anti-STAT3 and anti-GAPDH antibodies, n = 3. GAPDH was used
as loading control. Bar graph showing the ratio of the relative densities of pSTAT3 Y705 and STAT3 protein contents as detected C. (B) Quantitative
real-time polymerase chain reaction (qRT-PCR) analysis of Socs3 expression. mRNA expression was normalized to Gapdh. Data are presented as
mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. MW, molecular weight; min, minutes; IL-6, interleukin 6. (C) Representative light microscopy pic-
tures. Scale bar = 100 μm. (D) Frequency distribution histograms of cell width of IL-6 and solvent treated myotubes, n = 100 cells per condition. Mean
myotube width.
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Figure 3 Interleukin 6 mediates atrophy through gp130/JAK2/STAT3 signalling in myocytes. (A–D) Five days differentiated C2C12 myotubes were
transfected with control siRNA (control siRNA, 50 nM) (n = 6) or siRNA targeting Il6st/gp130 (Il6st siRNA, 50 nM) (n = 6) followed by treatment with
IL-6 (10 ng/mL) or vehicle control, as indicated, for 24 h. (A) Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of Il6st expression.
mRNA expression was normalized to Gapdh. (B) Western blot analysis with anti-gp130, anti-phospho-STAT3-Tyr705 (pSTAT3 Y705), anti-STAT3, and
anti-GAPDH antibodies, n = 3. GAPDHwas used as loading control. Bar graph showing the ratio of the relative densities of pSTAT3 Y705 and STAT3 protein
contents as detected in (B). (C) qRT-PCR analysis of Socs3 expression. mRNA expression was normalized to Gapdh. (D) Frequency distribution histograms
of cell width of IL-6 and vehicle-treated myotubes, n = 100 cells per condition. Bar graph showing mean myotube width. (E–H) Five days differentiated
C2C12 myotubes were treated with the JAK2 inhibitor AG490 (n = 6), the STAT3 inhibitor C188-9 (n = 6) or vehicle control prior to treatment with IL-6
(10 ng/mL) or solvent control, as indicated, for 24 h. (E), Western blot analysis with anti-phospho-STAT3-Tyr705 (pSTAT3 Y705), anti-STAT3, and anti-
GAPDH antibodies, n = 3. GAPDH was used as loading control. Bar graph showing the ratio of the relative densities of pSTAT3 Y705 and STAT3 protein
contents as detected (E). Data are shown as mean ± SD. (F) qRT-PCR analysis of Socs3 expression. mRNA expression was normalized to Gapdh. (G) Rep-
resentative lightmicroscopy pictures. Scale bar = 100 μm. Data are presented asmean ± SD. *P< 0.05, **P< 0.01, ***P< 0.001.MW,molecular weight,
IL-6, interleukin 6. (H) Frequency distribution histograms of cell width of IL-6 and vehicle-treatedmyotubes in the absence or presence of JAK2 and STAT3
inhibitors, and Il6st siRNA or scrambled siRNA control, as indicated, n = 100 cells per condition. Bar graph showing mean myotube width.
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weight, and IL-6 plasma levels (Table S3, Figure S7B). Septic
WT mice showed an increased STAT3 Y705 phosphorylation
in the TA, which was diminished in septic cKO mice 24 h after
CLP (Figure 4A). Socs3 expression was increased in the TA of
WT CLP, and this increase was attenuated in cKO after 24 h
(22-fold vs. 6-fold, P < 0.01; Figure S8A) and 96 h (22-fold
vs. 3.0-fold, P < 0.001; Figure 4B). These data indicate that
gp130 mediates STAT3 activation and Socs3 expression in
TA of septic mice. The observed reduction in TA (WT:
22.3%, cKO: 13.5%; P < 0.001; Figure 4C) and gastrocne-
mius/plantaris (GP) weights (WT: 19.7%, cKO: 7.7%;
P < 0.001; Figure 4G, Table S3) after 96 h of sepsis, was less
pronounced for both muscles in cKO mice (P < 0.001 for
both). ATPase-stained histological cross sections showed a re-
duction in MCSA of fast twitch/type II myofibres of septic WT
mice that was attenuated in TA (WT: 26.7%, cKO: 6.0%;
P < 0.001; Figure 4D–4F) and GP (WT: 39.1%, cKO:
21.5%; P < 0.001; Figure 4H–4J) of septic cKO mice. Immu-
noblotting of muscle protein lysates showed an increase in
MuRF1 protein levels in septic WT that was abolished in
cKO mice after 24 h (Figure S8B) and 96 h (Figure 4A). In con-
trast, we found no differences between the induction of
Trim63 and Fbxo32-mRNA expression in TA of WT CLP
(Trim63: 11.2-fold, P < 0.01; Fbxo32: 8.2-fold, P < 0.001)
and cKO CLP mice (Trim63: 9-fold, P < 0.001; Fbxo32: 8.4-
fold, P < 0.001) after 96 h of sepsis (Figure 4K and 4L). Ex-
pression of Myh2, encoding MyHC2a, was increased in TA
of septic cKO but not WT mice when compared with sham an-
imals (Figure 4M). In contrast, expression of Myh4, encoding
MyHC2b, was equally and significantly decreased in TA of WT
and cKO mice after 96 h of sepsis (Figure 4N). In summary,
these data indicate that gp130 activates STAT3/Socs3 in mus-
cle during sepsis and that Il6st deletion prevents
sepsis-induced muscle atrophy. This was associated with a re-
duction of MuRF1 protein levels in cKO mice.
JAK2 inhibition attenuates sepsis-induced muscle
atrophy in mice
To investigate the effect of pharmaceutical inhibition of the
JAK2/STAT3 pathway, we treated C57BL/6J mice with AG490
or solvent 1 h prior to CLP (AG490: n = 15; solvent: n = 15)
or sham surgery (AG490: n = 5; solvent: n = 5) and every
24 h until the experimental endpoint at 96 h after surgery.
Treatment with AG490 attenuated sepsis-induced STAT3
Y705 phosphorylation (P< 0.01, Figure 5A) and Socs3 expres-
sion (Figure 5B) in TA muscle. AG490 treatment reduced
sepsis-induced muscle weight loss (relative reduction 29.6%,
P < 0.05 in the TA, Figure 5C; relative reduction in GP
33.6%, P < 0.01, Figure 5G, Table S4) and reduction in MCSA
of fast twitch/type II myofibres (relative reduction 58.3%,
P < 0.001, in the TA, Figure 5D–5F; relative reduction
18.3%, P < 0.001 in GP, Figure 5H–5J). AG490-treatment at-
tenuated sepsis-induced increase in MuRF1 and Atrogin-1
protein contents (Figure 5A). Trim63 and Fbxo32 mRNA ex-
pression was increased in TA of vehicle-treated CLP mice
(CLP vs. sham: Trim63: 16.0-fold, P < 0.01; Fbxo32: 13.4-fold,
P < 0.001), which was attenuated by AG490 (CLP vs. sham:
Trim63: 3.0-fold; Fbxo32: 3.0-fold; both P < 0.05 vs. vehicle
CLP) (Figure 5K and 5L). Comparable results were obtained
in GP muscle (Figure S9A–S9D). Neither sepsis nor AG490
treatment had an effect on Myh2 mRNA expression in TA or
GP muscles (Figure 5M, Figure S9F). In contrast, sepsis de-
creased Myh4 mRNA expression in TA and GP, which was at-
tenuated by AG490 treatment (Figures 5N and S9G). In
summary, these data indicate that JAK2 inhibition attenuates
sepsis-induced skeletal muscle atrophy, which coincides with
Trim63/MuRF1, Fbxo32/Atrogin-1 and Myosin expression in
mice.
Interleukin 6 interferes with insulin-induced IRS-1/
Akt-signalling
RNAseq data from TA of septic WT mice showed a down-reg-
ulation of the gene signature of PI3K/Akt signalling (Figure
S2). Immunoblotting confirmed a decreased Akt S473 phos-
phorylation in TA of septic WT but not cKO mice (Figure
6A). To investigate the interaction between the IL-6 and insu-
lin pathways, we co-treated C2C12 myocytes with IL-6 and in-
sulin. Insulin treatment resulted in increased insulin receptor
substrate 1 (IRS-1) S636/639 and Akt S473 phosphorylation,
which was blocked by pretreatment with IL-6 (Figure 6B).
These data indicate that IL-6 inhibits insulin signalling, sug-
gesting that IL-6-induced atrophy is mediated by both an in-
creased protein degradation and a decreased protein
synthesis.
Discussion
Our novel findings are as follows. First, the IL-6/gp130/JAK2/
STAT3 target gene SOCS3 was increased in muscle of ICUAW
patients when compared with controls. Second, IL-6 caused
atrophy of C2C12 myotubes, which was attenuated by knock-
down of Il6st/gp130 and treatment with JAK2 or STAT3 inhib-
itors. Third, skeletal muscle specific deletion of Il6st and
pharmacological JAK2 inhibition by AG490 attenuated
sepsis-induced muscle atrophy in mice in vivo. Fourth, IL-6
promoted protein degradation and inhibited insulin signal-
ling, which might reduce muscular protein synthesis and
therefore protein homeostasis.
Recently, we showed that IL-1β and SAA1 are crucial for
muscle atrophy in sepsis and that both increased the mRNA
and protein expression of IL-6 as well as MuRF1/Trim63 and
Atrogin-1/Fbxo32.11,12,26 Together with our novel data, we
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Figure 4 Deletion of Il6st in skeletal myocytes attenuates sepsis-induced muscle atrophy in mice. Twelve- to 16-week-old male Il6st cKO mice and
wildtype (WT) littermates were subjected to cecal ligation and puncture (CLP) or sham surgery. Analyses were performed 24 h (for Western blot:
WT sham, n = 4; WT CLP, n = 6; KO sham, n = 4; KO CLP, n = 4) or 96 h (for qRT PCR and morphological analyses: WT sham, n = 6; WT CLP, n = 15;
KO sham, n = 6; KO CLP, n = 10) after surgery in tibialis anterior (TA) and gastrocnemius and plantaris (GP). (A) Western blot analysis with anti-
phospho-STAT3-Tyr705 (pSTAT3 Y705), anti-STAT3, anti-Atrogin-1, anti-MuRF1, and anti-GAPDH antibodies, n = 3. GAPDH was used as loading control.
Bar graph showing the ratio of the relative densities of pSTAT3 Y705 and STAT3 protein contents as detected in (A) as mean ± SD. Arrow denotes non-
specific (n.s.) signal. (B) Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of Socs3. mRNA expression was normalized to Gapdh.
Data are presented as mean ± SEM; **P < 0.01, ***P < 0.001. (C, G) Analyses of TA and GP muscle weights normalized to tibia length of the same
animal. (D, H) Metachromatic ATPase staining of histological cross-sections from TA and GP of sham or CLP operated WT and Il6st cKO mice. (E, I) Mean
myofibre cross-sectional area (MCSA) of TA and GP muscle. (F, J) Frequency distribution histograms of fast/type II MCSA of sham-treated and
CLP-treated Il6st cKO and WT mice of TA and GP muscle. Data are presented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001. (K–N) qRT-PCR
analysis of Trim63, Fbxo32, Myh2, and Myh4. mRNA expression was normalized to Gapdh. Data are presented as mean ± SEM; *P < 0.05,
**P < 0.01, ***P < 0.001.
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Figure 5 The JAK2 inhibitor AG490 attenuates sepsis-induced muscle atrophy in mice. Twelve- to 16-week-old male Il6st cKO and wildtype (WT) mice
were treated with the JAK2 inhibitor AG490 (n = 20, 10 μM) or vehicle (n = 20) and then subjected to cecal ligation and puncture (CLP) or sham surgery
(solvent sham, n = 5; solvent CLP, n = 15; AG490 sham, n = 5; AG490 CLP, n = 15). Analyses were performed 96 h after surgery in tibialis anterior (TA)
and gastrocnemius and plantaris (GP) of sham-treated and CLP-treated AG490 and vehicle-treated animals. (A) Western blot analysis with anti-
phospho-STAT3-Tyr705 (pSTAT3 Y705), anti-STAT3, anti-Atrogin-1, anti-MuRF1, and anti-GAPDH antibodies, n = 3. GAPDH was used as loading control.
Bar graph showing the ratio of the relative densities of pSTAT3 Y705 and STAT3 protein contents as detected in (A) as mean ± SD. Arrow denotes non-
specific (n.s.) signal. (B) Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of Socs3. mRNA expression was normalized to Gapdh.
Data are presented as mean ± SEM; ***P < 0.001. (C, G) Analyses of TA and GP muscle weights normalized to tibia length of the same animal. (D,
H) Metachromatic ATPase staining of histological cross-sections from TA and GP of sham and CLP operated AG490- and solvent-treated mice. (E, I)
Mean myofibre cross-sectional area (MCSA) of TA and GP muscle. (F, J) Frequency distribution histograms of fast/type II MCSA of sham-operated
and CLP-operated AG490-treated and solvent-treated mice. Data are presented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001. (K–N) Quanti-
tative real-time polymerase chain reaction (qRT-PCR) analysis of Trim63, Fbxo32, Myh2, and Myh4. mRNA expression was normalized to Gapdh. Data
are presented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
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propose that the atrophic effect of IL-1β and SAA1 is partially
mediated by IL-6. Our data are in accordance with previous
reports showing that gp130 via the JAK/STAT pathway medi-
ates muscle atrophy in a cancer cachexia mouse
model.15,27,28 Specifically, increased IL-6 plasma levels are as-
sociated with cachexia in various models of cancer, such as
Lewis lung carcinoma, colon cancer, and melanoma. In accor-
dance with our data, STAT3 inhibition attenuated
cancer-associated muscle wasting in mice bearing colon-26
carcinoma.16 Mice devoid of Il6st in myocytes were protected
from cancer cachexia, which was attributed to a reduced
Atrogin-1 expression, while MuRF1 was not analysed.27 How-
ever, compared with this cancer-cachexia model where only
mildly elevated IL-6 plasma levels were reported,27 we mea-
sured 10 times higher IL-6 levels in septic mice. In addition,
while cancer is a chronic condition, the cytokine storm in sep-
sis is acute. These differences may explain the different kinet-
ics of muscle wasting that develops gradually in cancer but
occurs rapidly in sepsis.
The JAK2 inhibitor AG490 attenuated sepsis-induced
muscle atrophy in vitro and in vivo. This was associated
with a reduced Trim63/MuRF1 and Fbxo32/Atrogin-1 ex-
pression. Peña et al. showed that AG490 leads to a reduc-
tion in TNF plasma levels in septic mice.29 In addition,
Figure 6 IL-6 inhibits insulin signalling in myocytes in vitro. (A) Twelve- to 16-week-old male Il6st cKO and wildtype (WT) mice were subjected to cecal
ligation and puncture (CLP) or sham surgery (WT sham, n = 4; WT CLP, n = 6; KO sham, n = 4; KO CLP, n = 4). Analyses were performed 24 h after
surgery. Western blot analysis with anti-Akt, anti-pAkt S473, and anti-GAPDH antibodies, n = 3. GAPDH was used as loading control. Bar graph showing
the ratio of the relative densities of pAkt S473 and Akt protein contents as detected in (A) as mean ± SD. (B) Five days differentiated C2C12 myotubes
were treated with IL-6 (10 ng/mL) or vehicle for 30 min (n = 6) before insulin-treatment for 1 h (n = 3). Western blot analysis with anti-Akt, anti-pAkt
S473, anti-STAT3, anti-pSTAT3 Y705, anti-pIRS1 S636/639, anti-IRS1, and anti-GAPDH antibodies, n = 3. GAPDH was used as loading control. Bar graph
showing the ratio of the relative densities of pAkt S473 and Akt as well as pSTAT3 Y705 and STAT3 protein contents mean ± SD; *P < 0.05, **P < 0.01,
***P < 0.001.
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Gyurkovska and Ivanovska found decreased IL-6 and IL-12
plasma levels as well as decreased numbers of T-cells and
monocytes in the peritoneal lavage of AG490 treated
mice with LPS-induced toxic shock.30 AG490 treatment
protected against liver and lung injury and improved
survival in CLP-induced sepsis and LPS-induced toxic shock
in mice.29–31 Therefore, we suggest that the anti-atrophic
effects of AG490 are not only mediated by inhibition of
muscular gp130 signalling but also by its systemic
anti-inflammatory effect. Based on our data, JAK2 inhibition
might be useful to treat or prevent muscle atrophy in sep-
sis. Indeed, different JAK inhibitors received approval for
clinical use in patients with polycythemia vera and primary
myelofibrosis, in which somatic JAK2 mutations are com-
mon. Treatment with the JAK1/2 inhibitor ruxolitinib re-
sulted in clinical improvements in polycythemia vera and
an increased survival in primary myelofibrosis.32,33 Because
of the good tolerability of JAK inhibitors and the improved
outcomes of JAK inhibitor-treated septic mice, it seems
feasible to investigate their effects in septic patients.
Our RNAseq data revealed an increased expression of
genes involved in insulin resistance and a decreased expres-
sion of genes involved in insulin signalling, suggesting that in-
sulin resistance also occurs in skeletal muscle of septic mice.
Our data presented here indicate that insulin resistance in
sepsis occurs at the post-insulin receptor level. IL-6 attenu-
ated insulin-induced IRS-1- and Akt-phosphorylation indica-
tive for insulin resistance. We also found that sepsis-
mediated Akt-inactivation was prevented in muscle of cKO
mice. This indicates improved insulin signalling and suggests
that gp130 signalling contributes to insulin resistance in mus-
cle of septic mice. Our findings are in accordance with previ-
ous reports that IL-6 induces insulin resistance in hepatocytes
and skeletal muscle cells.34 However, contradictory results
have been reported about the effects of IL-6 on Akt phos-
phorylation. For example, IL-6 was shown to increase Akt
phosphorylation and protein synthesis in muscle and mye-
loma cells.34,35 Others showed that the combined treatment
of HepG2 cells with insulin and IL-6 had no effect on Akt
phosphorylation.36 These discrepancies could be explained
Figure 7 The IL-6/gp130/JAK2/STAT3-pathway mediates sepsis-induced muscle atrophy. IL-6 plasma levels are increased in critically ill human patients
and mice with polymicrobial sepsis. IL-6 acts on myocytes via the gp130 and IL-6Rα-complex and activates JAK2- and STAT3-signalling, which leads to
an increased expression of SOCS3. SOCS3 functions as a negative regulator of cytokine signalling and inhibits the growth promoting insulin/insulin-re-
ceptor/Akt pathway by degradation of IRS-1. Reduction of IRS-1 is paralleled by a decreased Akt-activity that results in a reduced protein synthesis and
an increased protein degradation, which eventually mediate muscle atrophy. Inhibition of IL-6/gp130 signalling by IL6st-knockdown (e.g. Il6st siRNA
and Il6st cKO), JAK2 (e.g. AG490), or STAT3 inhibition (e.g. C188-9 and S3i-201) prevents IL-6-induced SOCS3 expression as well as myocyte atrophy
in vitro and skeletal muscle atrophy in vivo. Red arrows indicate changes related to increased IL-6 plasma levels. Fbxo32 indicates F-box protein 32;
Gp130, glycoprotein 130; IRS-1, insulin receptor substrate-1; IL-6, interleukin 6; IL-6Rα, interleukin 6 receptor alpha; JAK2, Janus kinase-2; MuRF1,
muscle-specific RING finger protein 1; PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, phosphatidylinositol 3-kinase; SOCS3, suppressor
of cytokine signalling 3; STAT3, signal transducer and activator of transcription 3; Trim63, tripartite motif containing 63. Created with BioRender.com.
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by the sensitivity of the model systems, the cell types and the
experimental setup used. In our hands, Akt phosphorylation
was significantly inhibited in the skeletal muscle of septic
mice. In addition, when we preincubated myocytes with
IL-6 prior to insulin treatment, insulin-induced IRS-1 and Akt
phosphorylation were attenuated, suggesting that IL-6 inter-
feres with insulin signalling in myocytes. Further studies are
needed to examine the mechanisms behind IL-6-induced in-
sulin resistance. Based on our data and the body of literature,
we conclude that in sepsis, IL-6 via the gp130/JAK2/STAT3/
SOCS3 pathway mediates skeletal muscle atrophy by increas-
ing protein degradation and decreasing protein synthesis.
Interestingly, we found a discrepancy between Trim63
mRNA expression and MuRF1 protein levels in muscle of sep-
tic cKO mice. Our data implicate that IL-6 does not increase
Trim63 expression, but possibly increases its translation or
its protein stability, or reduces its degradation. Further stud-
ies are needed to address this observation.
As a beta-receptor, gp130 is shared by the IL-6 cytokine fam-
ily consisting of IL-6, IL-11, CNF, LIF, OSM, CT-1, CLCF1, and IL-
27.37 Our RNAseq data showed that the expression of genes
involved in IL-6 signalling were increased in muscle of septic
mice, whereas the expression of the other IL-6 family mem-
bers and their receptors was not asmuch increased or even re-
duced. Increased IL-6 plasma levels are a risk factor for CIM,
and IL-6 strongly induces the JAK/STAT pathway and induces
myocyte atrophy in vitro. We therefore suggest that IL-6 plays
the predominant role among the IL-6 family for sepsis-induced
muscle atrophy. However, the involvement of other IL-6 family
members in ICUAW warrants further studies.
Conclusion
IL-6 plasma levels are increased in critically ill human patients
and mice with polymicrobial sepsis. IL-6 acts on myocytes via
the gp130 and IL-6Rα-complex and activates JAK2- and
STAT3-signalling, which leads to an increased expression of
SOCS3 (Figure 7). SOCS3 functions as a negative regulator of
cytokine signalling and inhibits the growth promoting insu-
lin/insulin-receptor/Akt pathway by degradation of IRS-1. Re-
duction of IRS-1 is paralleled by a decreased Akt-activity that
results in a reduced protein synthesis and an increased pro-
tein degradation, which eventually mediate muscle atrophy.
Inhibition of IL-6/gp130 signalling by IL6st-knockdown (e.g.
Il6st siRNA and Il6st cKO), JAK2 (e.g. AG490) or STAT3 inhibi-
tion (e.g. C188-9 and S3i-201) prevents IL-6-induced SOCS3
expression as well as myocyte atrophy in vitro and skeletal
muscle atrophy in vivo (Figure 7). In summary, IL-6 via the
gp130/JAK2/STAT3-pathway mediates sepsis-induced muscle
atrophy and possibly contributes to ICUAW. An inhibition of
this pathway in muscle could be beneficial to prevent
sepsis-induced muscle wasting.
Limitations
Our in vitro experiments were performed in murine C2C12
myotubes. Further analyses of primary murine and/or human
myocytes are needed to independently confirm our observa-
tions about the role of IL-6/gp130/JAK2/STAT3 signalling in
myocyte atrophy in vitro. In human patients, sepsis fre-
quently occurs at the extremes of ages, especially in elderly
patients. Here, we have used 12–20-week-old mice, which re-
lates to a young age in human patients. Although our data are
informative for a younger age, further studies on mature
(12-month-old) and aged mice (24-month-old) are needed38
to provide data that are more relevant to the elderly popula-
tion. Because, we have used only male mice for our experi-
ments, further sex-specific studies are needed to elucidate
if IL-6 signalling is equally important for sepsis-induced mus-
cle atrophy in female mice.
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of WT mice after 24 (left) or 96 hours (right) after CLP surgery
compared to sham treated controls (n = 3 for each condition).
Every tile (small polygon) represents one gene. Tiles are ar-
ranged and coloured according to the hierarchical KEGG
pathway maps (larger regions correspond to functional cate-
gories). The diagrams show three hierarchical KEGG pathway
levels (top three panels) and the level of individual genes
(bottom panel) per time point (24 hours: left panels, 96 hours:
right panels). Tile sizes represent changes in gene expression.
Figure S2. Genes up- and downregulated in muscle of septic
mice. Significantly up (top) or down (bottom) regulated
genes in TA muscle of WT mice 24 (left) or 96 hours (right)
after sham or CLP surgery. Analyses for GO-terms and
KEGG-pathways are shown (n = 3 for each condition). Data
are p-values and presented as -log10
Figure S3. Decreased Genes in muscle of septic mice. Venn
Diagram showing the number of genes that were decreased
(log2 fold change ≥2, adjusted p-value<0.01) in the tibialis
anterior muscle of CLP-treated compared to sham treated
mice after 24 (left) or 96 hours (right) or at both time points
(bottom) (n = 3 for each condition). Data are p-values and
presented as -log10.
Figure S4. Regulated genes involved in IL-6 production. Heat
map of genes contained in GO:0032635-IL-6 production that
were significantly regulated (p<0.05) in TA muscle of WT
mice 24 hours and 96 hours after CLP or sham surgery (n =
3 for each condition).
Figure S5. Regulated genes involved in JAK-STAT signalling.
Heat map of genes contained in GO:0007259-receptor signal-
ling pathway via JAK-STAT that were significantly regulated
(p<0.05) in TA muscle of WT mice 24 hours and 96 hours af-
ter CLP or sham surgery (n = 3 for each condition).
Figure S6. Inhibition of STAT3 attenuates IL-6 induced myo-
tube atrophy in vitro. Frequency distribution histograms
showing the width of differentiated C2C12 myocytes after
24 hours of treatment with solvent or IL6 after preincubation
with DMSO or S3i-201 (n = 100 cells for each condition). Bar
graph showing mean myotube width ± SEM. *P <0.05 (Stu-
dent’s t-test).
Figure S7. Deletion of Il6st in myocytes does not affect inter-
leukin 6 plasma levels in septic mice. (A) Quantitative
RT-PCR analysis of Il6st mRNA expression in TA muscle of
WT and Il6st cKO mice 96 hours after sham or CLP surgery
(WT: Sham n=6, CLP: n=15; cKO: Sham: n=6; CLP: n=10). (B)
IL-6 plasma concentrations from the same mice. Data infor-
mation: Data are presented as mean ± SEM. **P <0.01,
***P <0.001 (Mann-Whitney U test).
Figure S8. Deletion of Il6st in myocytes attenuates
sepsis-induced Socs3 expression and MuRF1 protein con-
tent. (A) Quantitative RT-PCR analysis of Socs3 mRNA content
in TA muscle of Il6st cKO and WT mice 96 hours after CLP or
sham operation (WT Sham, n=6; WT CLP, n=15; KO Sham,
n=6; KO CLP, n=10). Data are presented as mean ± SEM **P
< 0.01, ***P < 0.001 (Mann-Whitney U test). (B) Immuno-
blots with anti-Atrogin-1, anti-MuRF1 and anti-GAPDH anti-
bodies in TA muscle of Il6st cKO and WT mice 24 hours
after CLP or sham operation (n = 3 for each condition).
Figure S9. Inhibition of JAK2 attenuates sepsis-induced
Socs3 and Trim63 expression and MuRF1 protein content
in gastrocnemius and plantaris muscle. (A) Immunoblots
with anti-pSTAT3 Y705, anti-STAT3, anti-Atrogin-1,
anti-MuRF1 and anti-GAPDH antibodies in GP muscle of
AG490 or solvent treated WT mice 96 hours after CLP or
sham surgery (n = 3 for each condition). Bar graph showing
the ratio of the relative densities of pSTAT3 Y705 and STAT3
protein contents as detected in B. B-F Quantitative RT-PCR
analysis of Socs3 (B), Trim63 (C), Fbxo32 (D), Myh2 (E) and
Myh4 (F) mRNA expression in GP muscle of AG490 or solvent
treated WT mice 96 hours after CLP or sham surgery (AG490:
sham: n=5, CLP: n=15; solvent: sham: n=5, CLP: n=15). Data
information: (B-F) Data are presented as mean ± SEM. *P <
0.05, **P < 0.01 (Mann-Whitney U test).
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